Last reviewed · How we verify
Recombinant human urokinase
Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots.
Recombinant human urokinase is a thrombolytic agent that works by activating plasminogen to plasmin, which then breaks down blood clots. Used for Pulmonary embolism, Ischemic stroke.
At a glance
| Generic name | Recombinant human urokinase |
|---|---|
| Also known as | rhPro-UK |
| Sponsor | Tasly Biopharmaceuticals Co., Ltd. |
| Drug class | Thrombolytic |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This process is crucial in treating conditions such as pulmonary embolism and ischemic stroke. The drug's mechanism is based on its ability to dissolve blood clots, thereby restoring blood flow to affected areas.
Approved indications
- Pulmonary embolism
- Ischemic stroke
Common side effects
- Hemorrhage
- Allergic reactions
- Anaphylaxis
Key clinical trials
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PHASE3)
- SuPAR in Adult Patients With Covid-19
- Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) (PHASE3)
- Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |